BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Urgent support needed following the pandemic's effect on cancer screening services

Dry July Foundation is urging Australians to dig even deeper this Dry July to help people affected by cancer. So many Australians could not access vital li...

July 15, 2022 | News

Tampa General Hospital Offers New Treatment Option for Recurrent Brain Cancer to Improve Quality of Life

Tampa General Hospital and USF Health Morsani College of Medicine physicians are the first in Hillsborough County to bri...

July 11, 2022 | News

ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment

TLX250-CDx, which has received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA)1, is being developed as an imaging agent for use...

July 11, 2022 | News

Seoul National University Hospital selects RayCare to advance oncology system

In April 2022 the carbon ion center at SNUH ordered RayStation treatment planning system, for use with their Toshiba Heavy Ion Therapy System. Th...

July 04, 2022 | News

Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) Merck now one of industry’s largest manufacturer...

June 24, 2022 | News

Australia’s PrOSPeCT Project Is Sequencing Thousands of Cancer Patients

This March, Australia launched the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), which will sequence the genomes of more t...

June 23, 2022 | News

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients Priority Review requested; if accepted, anticipate an 8-mont...

June 23, 2022 | News

JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

New research in the June 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical tri...

June 22, 2022 | News

DTx Leader Sidekick Enters Strategic Collaboration with Lilly to Support Patients with Breast Cancer

International digital therapeutics (DTx) innovator, Sidekick Health (www.sidekickhealth.com), today announces an integrated digital therape...

June 20, 2022 | News

Emmes Supports Groundbreaking Anal Cancer Study Sponsored by the National Cancer Institute

Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovatio...

June 17, 2022 | News

Nonagen Bioscience announces CE mark for Oncuria® bladder cancer diagnostic

Oncuria is the first-of-its-kind multiplex urine test for the quantitative detection of 10 biomarkers in urine that are associated with the presence of...

June 17, 2022 | News

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotech...

June 16, 2022 | News

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative im...

June 07, 2022 | News

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02

Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the prima...

June 06, 2022 | News

Stay Connected